MONDAY, AUGUST 17

Keynote Address
James P. Allison, University of Texas MD Anderson Cancer Center, USA
Immune Checkpoint Blockade in Cancer Therapy: New Insights into Therapeutic Mechanisms

Mechanisms of Action I
*Ira Mellman*, Genentech, Inc., USA
Mechanistic Basis of Cancer Immunotherapy
*Kelli Connolly*, Yale University, USA
Short Talk: Tumor-Draining Lymph Nodes Contain an Untapped Reservoir of Stem-Like CD8 T Cells

AHyun Choi, Novartis Institutes for BioMedical Research, USA
Short Talk: Loss of EMC Inhibits Tumor Growth through Enhanced Adaptive Immune Response

Mechanisms of Action II
Jane Oliaro, Peter MacCallum Cancer Centre, Australia
Identifying New Targets for Cancer Immunotherapy
Vandana Kalia, University of Washington and Seattle Children’s Research Institute, USA
Short Talk: PD-1 Signals Are Critical for Maintenance of CD8 T Cell Memory

Katie Campbell, University of California, Los Angeles, USA
Short Talk: Integrating DNA and RNA Sequencing Analysis to Describe Somatic Alterations and Expression in the HLA Gene Loci

Stephen Mok, MD Anderson Cancer Center, USA
Short Talk: Late Interferon-Gamma Blockade Improves Antitumor Efficacy of Anti-CTLA-4 and Anti-PD-1 Combination Treatment

Mechanisms of Response I
*Siwen Hu-Lieskovan*, Huntsman Cancer Institute, USA
Clinical Testing Strategies against Heterogenous Mechanisms of Immune Resistance
Antoni Ribas, University of California, Los Angeles, USA
Mechanisms of Primary and Acquired Resistance to PD-1 Blockade Therapy
Chang Liu, University of Pittsburgh, USA
Short Talk: Neurupilin-1 Is a T Cell Memory Checkpoint Limiting Long-Term Anti-Tumor Immunity

Mechanisms of Response II
Padmanee Sharma, University of Texas MD Anderson Cancer Center, USA
From the Clinic to the Lab: Investigating Mechanisms of Response and Resistance to Immune Checkpoint Therapy
*Yuxuan Miao*, Rockefeller University, USA
Short Talk: Adaptive Immune Resistance Emerges From Tumor-Initiating Stem Cells

Shira Tabachnick-Cherny, University of Washington, USA
Short Talk: Characterization of Myeloid Cells Subsets in the Tumor Microenvironment of Merkel Cell Carcinoma

Zoila Areli Lopez Bujanda, NYU, USA
Short Talk: ADT-Mediated Intra-Tumoral Myeloid Infiltration Promotes Resistance to Immune Checkpoint Blockade in Prostate Cancer

Poster Session

TUESDAY, AUGUST 18

Therapeutic Play I
*Yvonne Y. Chen*, University of California, Los Angeles, USA
Engineering Next-Generation CAR-T Cell Therapy for Cancer
*Coralie Backlund*, Massachusetts Institute of Technology, USA
Short Talk: Cell Penetrating Peptides Improve T Cell Response to Neoantigen Peptide Vaccines

Majia Holmén, University of Turku, Finland
Short Talk: Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumours

Yangxiao Wang, University of California, San Diego, USA
Short Talk: Engineering Remotely Controllable CAR T Cells for Cancer Immunotherapy

Therapeutic Play II
*Evan Scott*, Northwestern University, USA
Engineered Nanobiomaterials for Cancer Immunotherapy
E. John Wherry, University of Pennsylvania, USA
Epigenetic Features of Exhausted Antitumor T Cells

Buvana Ravishankar, Rapt Therapeutics, Inc., USA
Short Talk: Targeting the Stress Response Kinase GCN2 Potentiates Anti-Tumor Immune Response

Anthony K. Park, City of Hope, USA
Short Talk: Effective Combination Immunotherapy using Oncolytic Viruses to Deliver CAR Targets to Solid Tumors

Patrick A. Ott, Dana-Farber Cancer Institute, USA
Short Talk: Personal Neoantigen Vaccines Induce Long-term Immune Responses in Patients with High Risk Melanoma

Meet-the-Editors Roundtable
Alessandra Fornarelli, Frontiers, Switzerland
Paloma Portela Torres, SAGE Publications Ltd, UK
Lise Roth, European Molecular Biology Organization, Germany

Genomics of Cancer I
*Priti Hegde*, Foundation Medicine, USA
Pan-Cancer Analysis of Allele-Specific HLA-I Loss Suggests Widespread Occurrence across a Diverse Range of Tumor Types
Eliezer M. Van Allen, Dana-Farber Cancer Institute, USA
Tumor Genomics and Selective Response to Cancer Immunotherapy

For the most up-to-date details, visit [https://www.keystonesymposia.org](https://www.keystonesymposia.org).
*Nadine A. Defranoux*, Parker Institute for Cancer Immunotherapy, USA  
*Short Talk: Strategies to Improve the Sensitivity and Ranking Ability of Neoantigen Prediction Methods: Report on the Results of the Tumor neoantigen SeLecion Alliance (TESLA)*

**Gloria Bora Kim**, University of Pennsylvania, USA  
*Short Talk: Splice Variants as Neoantigens for Cancer Immunotherapy*

**Genomics of Cancer II**

**Elaine R. Mardis**, Nationwide Children's Hospital, USA  
*Immunogenomics and the TME in Pediatric CNS Cancers*

**Thomas D. Wu**, Genentech, Inc., USA  
*Short Talk: Peripheral T Cell Expansion Predicts Tumor Infiltration and Clinical Response to Cancer Immunotherapy*

**Debattama Sen**, Massachusetts General Hospital, USA  
*Short Talk: Disrupting Enhancers within the Core Epigenetic Program of Exhaustion Improves CD8+ T Cell Responses and Enhances Tumor Control*

**WEDNESDAY, AUGUST 19**

**Single Cell I**

**James R. Heath**, Institute for Systems Biology, USA  
*Single Cell Approaches to Analyzing Antitumor Responses*

*Ansuman Satpathy*, Stanford University School of Medicine, USA  
*Single-Cell Genomics in Cancer Immunotherapy*

**Christine Carine Moussion**, Genentech, Inc., USA  
*Short Talk: Local Heterogeneity of Response to CIT: Learning from the STAMP Live Imaging Model*

**James C. Lee**, University of California, San Francisco, USA  
*Short Talk: Liver Metastasis Mediated Control of Systemic Tumor-Specific Immunity and Response to Checkpoint Immunotherapy*

**Single Cell II**

*Soheil F. Tavazoie*, Rockefeller University, USA  
*Depleting Myeloid-Suppressive Cells for Cancer Immunotherapy*

**Theodore Roth**, University of California, San Francisco, USA  
*Short Talk: Parallel Engineering of Immune Cell Genomes by Pooled Knockin Targeting*

**Amanda Oliver**, Peter MacCallum Cancer Centre, Australia  
*Short Talk: Tissue-Specific Tumour Microenvironments Influence Responses to Immunotherapy*